A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.
Chronic Myeloid Leukemia
DRUG: dasatinib
rate of Major Molecular Responses (MMR) in chronic phase chronic myeloid leukemia subjects, at 12 months
safety after treatment with dasatinib, 2 year|rate of Complete Cytogenetic Response(CCyR), 2 year|rate of Complete Hematologic Response (CHR), 2 year|efficacy on patients with BCR-ABL point mutations, 2 year|progression free survival, 2 year
The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.